RICHARD I. FISHER, M.D.; VINCENT T. DeVITA Jr., M.D.; FRIEDA BOSTICK, B.S.; CHRISTIAN VANHAELEN, M.D.; DIANNE M. HOWSER, R.N., B.S.; SUSAN M. HUBBARD, R.N., B.S.; ROBERT C. YOUNG, M.D.
Immunologic studies were done on 47 long-term survivors of Hodgkin's disease who had been treated with MOPP chemotherapy (mechlorethamine, vincristine, procarbazine, and prednisone). Percentages of E rosettes and mitogen-induced lymphocyte proliferation were significantly reduced compared to those in normal control subjects. There was no tendency for these abnormalities to return to the normal range with increasing disease-free intervals. No abnormalities of B-cell number or function were detected. Long-term survivors of advanced diffuse histiocytic lymphoma treated with comparable chemotherapy, who served as a control population, had significantly higher percentages of E rosettes and no reduction in mitogen-induced lymphocyte proliferation. Thus these persistent immunologic abnormalities cannot be attributed to chemotherapy alone. The presence of similar immunologic abnormalities in untreated patients with Hodgkin's disease of all stages and in patients cured by either MOPP or radiotherapy suggests that depressed cellular immunity may be an inherent characteristic of the person in whom Hodgkin's disease develops.
Learn more about subscription options.
Register Now for a free account.
FISHER RI, DeVITA VT, BOSTICK F, VANHAELEN C, HOWSER DM, HUBBARD SM, et al. Persistent Immunologic Abnormalities in Long-Term Survivors of Advanced Hodgkin's Disease. Ann Intern Med. 1980;92:595–599. doi: 10.7326/0003-4819-92-5-595
Download citation file:
Published: Ann Intern Med. 1980;92(5):595-599.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only